drugset
drugset / Trial / NCT04555096

A Trial of GC4419 in Patients With Critical Illness Due to COVID-19

NCT04555096 ↗

Phase 2 Terminated 16 enrolled Galera Therapeutics, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Trial of GC4419 in Patients with Critical Illness due to COVID-19

Timeline

Start
2020-09-09
Primary completion
2021-05-28
Completion
2021-05-28

Outcome

Outcome not reported

Stopped: “Participants are no longer receiving intervention”

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Avasopasem manganese Other / unclassified — Intravenous

Indications

COVID-19